Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pruritus, Vaccination site urticaria
Clinical narrative: rash, but this time with itching; chills,; fatigue; night sweats; numbness; Drenching night sweats; Itching local; Hives/Urticaria local; Redness Local; This spontaneous case was reported by a consumer and describes the occurrence of NIGHT SWEATS (night sweats), RASH PRURITIC (rash, but this time with itching), HYPOAESTHESIA (numbness), HYPERHIDROSIS (Drenching night sweats) and VACCINATION SITE PRURITUS (Itching local) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002B21A, and 032L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Drug allergy (Benadryl - nausea, vomiting and weakness) since 1959, Drug allergy (Aubagio - Diarrhea), Multiple sclerosis (Wobbly walking) since 09-Sep-2011, Hypothyroidism since 1970 and Hypertension since 2008. Concomitant products included AMLODIPINE from 24-Jul-2020 to an unknown date and LOSARTAN from 24-Jul-2020 to an unknown date for Hypertension, LEVOTHYROXINE for Hypothyroidism.   On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Mar-2021, the patient experienced HYPOAESTHESIA (numbness), HYPERHIDROSIS (Drenching night sweats), VACCINATION SITE PRURITUS (Itching local), VACCINATION SITE URTICARIA (Hives/Urticaria local) and VACCINATION SITE ERYTHEMA (Redness Local). On 18-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced NIGHT SWEATS (night sweats), CHILLS (chills,) and FATIGUE (fatigue). On an unknown date, the patient experienced RASH PRURITIC (rash, but this time with itching). The patient was treated with TRIAMCINOLONE ACETONIDE for Rash, at a dose of 1 dosage form and BETAMETHASONE (topical) ongoing from 05-Apr-2021 at a dose of 1 dosage form twice a day. On 20-Mar-2021, NIGHT SWEATS (night sweats), CHILLS (chills,) and FATIGUE (fatigue) had resolved. At the time of the report, RASH PRURITIC (rash, but this time with itching) outcome was unknown and HYPOAESTHESIA (numbness), HYPERHIDROSIS (Drenching night sweats), VACCINATION SITE PRURITUS (Itching local), VACCINATION SITE URTICARIA (Hives/Urticaria local) and VACCINATION SITE ERYTHEMA (Redness Local) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 13-May-2021, Biopsy cervix: inconclusive (Inconclusive) Inconclusive. On 27-May-2021, Antibody test (0.0-19.99 unit): normal unit (normal) SS-A/SS-B Antibody - Anti- RO Antibody & Anti-LA Antibody - Both are normal. On 27-May-2021, Antinuclear antibody: positive (Positive) ANA - Positive and inconclusive (Inconclusive) ANA Pattern - Speckled.         The action taken with the mRNA-1273 was considered as not applicable  It was reported that the patient used ice to treat rash after the first dose of vaccination.  It was also reported that the prescription was changed on 13-MAY-2021, as the previous topical application yielded no positive results.   Most recent FOLLOW-UP information incorporated above includes: On 09-Jun-2021: Follow up received on 09-jun-2021 and has no significant information On 23-Jun-2021: Followup received on 23-JUN-2021 contains updated information regarding the demographics of the patient, Medical History details, Laboratory data, Concomitant drug information, Events And their outcomes.